Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAV+ STH Clinical Trial
PACTR202606846629607Phase 3Recruiting
- Sponsor
- Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of albendazole, praziquantel and ivermectin in trichuriasis, Soil-Transmitted Helminthiases (STH) and schistosomiasis (3 arms), sponsored by Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa. Primary endpoint: Parasitological cure rate for Trichuris trichiura. Started Jun 2026; status: recruiting.
02
Drugs
albendazolepraziquantelivermectin
03
Conditions
trichuriasisSoil-Transmitted Helminthiases (STH)schistosomiasis
Beyond the preview
Go deeper on PACTR202606846629607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202606846629607.